Overview
The Netherlands reports an average score in the Policy Context category, in part due to the existence of a national asthma strategy and severe asthma guidelines. However, limited alignment of national guidelines with international best practices and tobacco control laws lowers the Netherlands’ score. In terms of Access and Care Coverage, the Netherlands scores second compared to all other countries. This is due to excellent access to treatment (including biologics), diagnostics, and telemedicine – though the Netherlands could improve access to specialist care and digital therapeutics. Notably, the Netherlands ranks among the lowest in terms of Disease Burden score. This is attributable to a high estimated societal cost of severe asthma and DALYs attributable to asthma, as well as adult tobacco use and obesity rates slightly higher than the average.
How does Netherlands perform in each category?
Provides further insights into how Netherlands scores across each Index category
Netherlands takeaways
Data from the Severe Asthma Index revealed the following key insights about severe asthma care in Netherlands
The Netherlands has a strong asthma strategy and severe asthma guidelines as well as contributing data to a severe asthma registry
The Netherlands has the second highest score in Access and Care Coverage, though limited access to specialist care
The Netherlands has a low score in Disease Burden with high societal cost and DALYs attributable to asthma
Compare Netherlands to other countries
Select different countries to see how they scored across each of the 5 categories and overall